Patient enjoying normal daily activity, like cooking, while safely wearing the prescribed ASSURE wearable defibrillator.

Patient interacting happily with children in bed, carrying the ASSURE monitor over the shoulder, while wearing the defibrillator vest under clothing.

Older couple sharing a tender moment, with the ASSURE monitor visible, underscoring patient independence with the defibrillator vest.

Kestra's Mission

We provide innovative, intuitive medical technologies to protect and support at-risk patients.

Advancing SCA Risk Management:
Insights from the ACE-PAS Trial

The ASSURE^® WCD Clinical Evaluation Post-Approval Study (ACE-PAS)—the largest prospective real-world study of wearable defibrillators to date—provides contemporary evidence on the performance, safety, and real-world use of the ASSURE^® Wearable Cardioverter Defibrillator (WCD).

In this on-demand panel discussion hosted by MedAxiom, leading investigators and clinical experts review the study’s design and outcomes and share their perspectives on how ACE-PAS may help inform care decisions for patients at elevated risk of SCA.

Review the Findings

We work at the intersection of digital healthcare, smart wearables, mobile connectivity, and lifesaving medical technology.

Sudden Cardiac Arrest is a Leading Cause of Death

Sudden cardiac arrest (SCA) claims the life of 475,000¹ people in the United States each year. SCA occurs when the heart stops beating normally due to an electrical malfunction in the heart, typically caused by ventricular arrhythmias. It can lead to a loss of consciousness and potentially death if not treated within minutes. Approximately 70% of SCAs occur at a home or residence and about 50% of those are unwitnessed. Rapid defibrillation is the only proven therapy to reverse sudden cardiac arrest.

1 https://cpr.heart.org/en/resources/cpr-facts-and-stats 2 Virani et al., Circulation 2021;143:e254-e743

Clinician consulting with an older patient and partner regarding the serious risk of Sudden Cardiac Arrest (SCA) and ASSURE system WCD prescription.

Low Cardiac Output Patients
are at
Higher Risk of SCA

Heart failure (HF) patients and patients with low left ventricular ejection fraction (low LVEF) of 35% or below are at elevated risk of SCA while waiting for their condition to improve or until eligible for subsequent therapy.

Wearable Cardioverter Defibrillators (WCDs) are non-invasive, monitor around the clock, and can protect patients who are at known risk for SCA.

Male patient with low LVEF getting dressed while wearing the discreet ASSURE system wearable cardioverter defibrillator (WCD).

Close-up of patient positioning hand over the HeartPoint Alert Button on the ASSURE monitor for safety and management.

Cardiac Recovery System^®

The ASSURE system from Kestra is a modern WCD offering integrated sensing, autonomous detection, and highly effective defibrillation therapy. The system includes the Kestra CareStation™ remote patient data platform, designed to provide robust management of at-risk cardiac patients, and the ASSURE patient application to engage patients in their own recovery and care.

The components work in concert to promote patient compliance while offering protection during normal patient activities.